21610160|t|Ataxin-2 repeat-length variation and neurodegeneration.
21610160|a|Expanded glutamine repeats of the ataxin-2 (ATXN2) protein cause spinocerebellar ataxia type 2 (SCA2), a rare neurodegenerative disorder. More recent studies have suggested that expanded ATXN2 repeats are a genetic risk factor for amyotrophic lateral sclerosis (ALS) via an RNA-dependent interaction with TDP-43. Given the phenotypic diversity observed in SCA2 patients, we set out to determine the polymorphic nature of the ATXN2 repeat length across a spectrum of neurodegenerative disorders. In this study, we genotyped the ATXN2 repeat in 3919 neurodegenerative disease patients and 4877 healthy controls and performed logistic regression analysis to determine the association of repeat length with the risk of disease. We confirmed the presence of a significantly higher number of expanded ATXN2 repeat carriers in ALS patients compared with healthy controls (OR = 5.57; P= 0.001; repeat length >30 units). Furthermore, we observed significant association of expanded ATXN2 repeats with the development of progressive supranuclear palsy (OR = 5.83; P= 0.004; repeat length >30 units). Although expanded repeat carriers were also identified in frontotemporal lobar degeneration, Alzheimer's and Parkinson's disease patients, these were not significantly more frequent than in controls. Of note, our study identified a number of healthy control individuals who harbor expanded repeat alleles (31-33 units), which suggests caution should be taken when attributing specific disease phenotypes to these repeat lengths. In conclusion, our findings confirm the role of ATXN2 as an important risk factor for ALS and support the hypothesis that expanded ATXN2 repeats may predispose to other neurodegenerative diseases, including progressive supranuclear palsy.
21610160	0	8	Ataxin-2	Gene	6311
21610160	37	54	neurodegeneration	Disease	MESH:D019636
21610160	90	98	ataxin-2	Gene	6311
21610160	100	105	ATXN2	Gene	6311
21610160	121	150	spinocerebellar ataxia type 2	Disease	MESH:D020754
21610160	152	156	SCA2	Disease	MESH:D020754
21610160	166	192	neurodegenerative disorder	Disease	MESH:D019636
21610160	243	248	ATXN2	Gene	6311
21610160	287	316	amyotrophic lateral sclerosis	Disease	MESH:D000690
21610160	318	321	ALS	Disease	MESH:D000690
21610160	361	367	TDP-43	Gene	23435
21610160	412	416	SCA2	Disease	MESH:D020754
21610160	417	425	patients	Species	9606
21610160	481	486	ATXN2	Gene	6311
21610160	522	549	neurodegenerative disorders	Disease	MESH:D019636
21610160	583	588	ATXN2	Gene	6311
21610160	604	629	neurodegenerative disease	Disease	MESH:D019636
21610160	630	638	patients	Species	9606
21610160	851	856	ATXN2	Gene	6311
21610160	876	879	ALS	Disease	MESH:D000690
21610160	880	888	patients	Species	9606
21610160	1029	1034	ATXN2	Gene	6311
21610160	1067	1097	progressive supranuclear palsy	Disease	MESH:D013494
21610160	1204	1237	frontotemporal lobar degeneration	Disease	MESH:D057174
21610160	1239	1274	Alzheimer's and Parkinson's disease	Disease	MESH:D010300
21610160	1275	1283	patients	Species	9606
21610160	1623	1628	ATXN2	Gene	6311
21610160	1661	1664	ALS	Disease	MESH:D000690
21610160	1706	1711	ATXN2	Gene	6311
21610160	1744	1770	neurodegenerative diseases	Disease	MESH:D019636
21610160	1782	1812	progressive supranuclear palsy	Disease	MESH:D013494
21610160	Association	MESH:D013494	6311
21610160	Association	MESH:D000690	23435
21610160	Association	23435	6311
21610160	Association	MESH:D000690	6311
21610160	Association	MESH:D057174	6311
21610160	Association	MESH:D019636	6311
21610160	Association	MESH:D020754	6311

